Activity Dates: 09/28/2020 - 03/25/2021
This self-study activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and health care providers seeking advanced education in patient and disease state management in the field of psychiatric pharmacy.
This application-based BCPP Recertification product provides the opportunity to study a complex psychiatric case comorbid with a medical diagnosis and associated complex medication regimen. A patient is followed over three encounters with each one consisting of a case study, pre-recorded webinar, and self-assessment questions. This edition is geriatric-focused, and the three encounters include delirium, dementia, and behavioral and psychological symptoms of dementia (BPSD). In the first encounter, the case explores a patient who has developed delirium during a hospitalization from both predisposing and precipitating factors. The webinar reviews diagnostic criteria, precipitating and predisposing factors, and a summary of guideline recommendations on the prevention and treatment of delirium. In the second encounter, the patient case focuses on dementia onset and adverse effects from cholinesterase inhibitors. The webinar reviews major neurocognitive disorder due to Alzheimer’s disease diagnostic criteria, treatment guidelines, an overview of cholinesterase inhibitors and memantine, and highlights important medication trials from the past several years. Lastly, the third case encounter finds the patient experiencing BPSD. The webinar reviews treatment guidelines, nonpharmacologic strategies, and pharmacologic treatment options and risks for BPSD. NEW-Given this geriatric focus, CPNP is working with ASCP to provide 5 hours of Board Certified Geriatric Pharmacy (BCGP) credit for this product in addition to BCPP credit provided by CPNP.
The activity design allows for the opportunity to apply evidence-based pharmacological and/or nonpharmacological treatment strategies and monitoring recommendations specific to patient needs and their pertinent medical, psychosocial, family, cultural and socioeconomic issues. Instructional webinars and a comprehensive, referenced key extends the value of the activity long after completion.
The From Theory to Practice Case Series includes electronic access to:
IMPORTANT NOTE: Since this product involves progression through a patient case over a period of time, it is highly recommended by the Editorial Board and past users, that you carve out 5 hours for the course and complete all in 1 sitting.
To satisfactorily complete the From Theory to Practice Case and receive 5 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:
You will proceed through the following steps to satisfactorily complete this course:
Participants successfully passing the required assessment/examination will obtain both ACPE and BCPP recertification credit. Credit is awarded in the calendar year the assessment is completed. ACPE credit is reported through CPE Monitor within days of examination submission, while BCPP recertification credit is reported to BPS within 6 weeks after the examination deadline.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Chris Paxos, PharmD, BCPP, BCPS, BCGP
View biographical information and disclosures
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The From Theory to Practice Case Series product is an application-based program approved for 5 ACPE hours. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination.
Board Certified Psychiatric Pharmacists (BCPPs) may also receive 5 hours of BCPP Recertification Credit for the From Theory to Practice Case Series upon successful completion of an online examination. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed.
Board Certified Geriatric Pharmacists (BCGPs) may also receive 5 hours of BCGP Recertification Credit for the From Theory to Practice Case Series upon successful completion of an online examination. BCGP Recertification credit is earned and reported within the year the assessment is successfully completed.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
2020 From Theory to Practice Case Series Editorial Board
|
Nancy C. Brahm, PharmD, MS, BCPP Adjunct Clinical Professor University of Oklahoma Oklahoma City, OK No Relevant Financial Relationships to Disclose |
|
Robin N. Hieber, PharmD, BCPP Clinical Pharmacy Specialist & Residency Director Captain James A. Lovell Federal Health Care Center North Chicago, IL |
Rex S. Lott, PharmD, BCPP |
Leigh Anne Nelson, PharmD, BCPP |
|
Stephanie V. Phan, PharmD, BCPP Clinical Pharmacist Researcher Health Services Advisory Group Tampa, FL External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Medical Writing Contracting for Forward We Go |
Jill Reynoldson, PharmD, BCPP |
|
Rosana Steavenson, PharmD, BCPP, BCPS Vice Chair Clinical Pharmacy Specialist - Psychiatry South Texas Veterans Health Care System San Antonio, TX No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational uses of the following medications for the prevention or treatment of delirium: Amisulpride, Haloperidol, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Ziprasidone, Ketamine, Melatonin, Ramelteon, Suvorexant, Dexmedetomidine, HMG-CoA reductase inhibitors, Cholinesterase inhibitors. My presentation will include discussion of off-label, experimental, and /or investigational uses of the following medications for the prevention or treatment of dementia: Estrogen, Progestin, Raloxifene, Gingkgo biloba, Nonsteroidal anti-inflammatory drugs, Antihypertensive agents, Omega-3 fatty acids, Vitamin E. My presentation will include discussion of off-label, experimental, and /or investigational uses of the following medications for the prevention or treatment of BPSD: Aripiprazole, Carbamazepine, Cholinesterase inhibitors, Clozapine, Dextromethorphan/Quinidine, Haloperidol, Lithium, Mirtazapine, Olanzapine, Paroxetine, Quetiapine, Risperidone, Serotonin norepinephrine reuptake inhibitors, Selective serotonin reuptake inhibitors, Trazodone, Tricyclic antidepressants, Valproate.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
